Effect of Age on Clinical Outcomes in Phase 1 Trial Participants
Authors:
Open Access
- 1 April 2015
- journal article
- other
- Published by SAGE Publications in Cancer Control
- Vol. 22 (2) , 235-241
Abstract
Background: Most persons with cancer living in the United States are older than 65 years of age; however, in general, elderly persons are under-represented in clinical trials and outcomes data are lacking. Methods: Outcomes data were analyzed of elderly participants (≥ 65 years of age) enrolled in phase 1 clinical trials and the results compared with those of younger patients. All consecutive, single-center, phase 1 oncology trials initiated and completed at the H. Lee Moffitt Cancer Center & Research Institute between 1997 and 2007 were included. Patient data (including survival, response, and toxicity rates) were extracted from a cancer registry database and electronic medical records at Moffitt Cancer Center. Results: After excluding multi-institution trials, we analyzed 39 trials for a total of 1,162 enrolled study participants, 32.7% of whom were elderly. Among patients who underwent transplantation, median survival rates were worse in those who were elderly compared with those who were younger (44.9 vs 32.9 months; P = .0037). However, in the no-transplantation setting, participants who were elderly had a median survival rate of 10.9 months (95% confidence interval [CI]: 8.9–13.1) compared with 8.8 months (95% CI: 7.9–10.3) in those who were younger (P = .15). Both groups had similar overall response rates (15.2% vs 13.1%) and similar treatment-related mortality rates (1% vs 0.9%, respectively). Adverse events occurring among the elderly and younger participants were not statistically significant. Conclusions: Survival, response, toxicity, and treatment-related mortality rates were not significantly different between the elderly and younger phase 1 trial participants in the no-transplantation setting. Regardless of the complex pharmacological profiles and logistical issues involved in treating the elderly population, our data imply that elderly study participants do at least as well as their younger counterparts, contributing to the justification of increasing the phase 1 trial enrollment of elderly patients.Keywords
This publication has 28 references indexed in Scilit:
- Inclusion of frail elderly patients in clinical trials: Solutions to the problemsJournal of Geriatric Oncology, 2013
- Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemiaJournal of Geriatric Oncology, 2011
- Participation and survival of geriatric patients in Phase I clinical trials: The Karmanos Cancer Institute (KCI) experienceJournal of Geriatric Oncology, 2011
- How Does Older Age Influence Oncologists' Cancer Management?The Oncologist, 2010
- Adjuvant Chemotherapy in Older Women with Early-Stage Breast CancerNew England Journal of Medicine, 2009
- Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave RoussyAnnals of Oncology, 2007
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBlood, 2006
- Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical TrialsThe Oncologist, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999